INVA Logo

Innoviva, Inc. (INVA) 

NASDAQ
Market Cap
$1.19B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
576 of 774
Rank in Industry
312 of 432

Largest Insider Buys in Sector

INVA Stock Price History Chart

INVA Stock Performance

About Innoviva, Inc.

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has …

Insider Activity of Innoviva, Inc.

Over the last 12 months, insiders at Innoviva, Inc. have bought $0 and sold $0 worth of Innoviva, Inc. stock.

On average, over the past 5 years, insiders at Innoviva, Inc. have bought $4.38M and sold $130.77M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 62,000 shares for transaction amount of $814,196 was made by DENNER ALEXANDER J (10 percent owner) on 2023‑06‑15.

List of Insider Buy and Sell Transactions, Innoviva, Inc.

2023-11-15SaleChief Accounting Officer
10,994
0.0173%
$13.99$153,810+15.23%
2023-06-15Purchase10 percent owner
62,000
0.0912%
$13.13$814,196+11.20%
2023-06-06Purchase10 percent owner
8,000
0.0118%
$13.05$104,384+10.38%
2023-06-05Purchase10 percent owner
7,000
0.0102%
$13.04$91,297+9.09%
2023-05-30Purchase10 percent owner
120,000
0.1775%
$13.01$1.56M+7.09%
2023-05-26Purchase10 percent owner
30,000
0.0442%
$13.12$393,729+5.71%
2023-05-25Purchase10 percent owner
50,000
0.0735%
$13.09$654,330+5.62%
2023-05-19Purchase10 percent owner
36,000
0.0531%
$13.48$485,147+1.71%
2023-05-18Purchase10 percent owner
10,000
0.0146%
$13.05$130,538+3.77%
2023-05-17Purchase10 percent owner
50,000
0.0736%
$13.07$653,690+4.46%
2023-05-11Purchase10 percent owner
290,000
0.4246%
$12.34$3.58M+9.90%
2023-03-10PurchaseChief Executive Officer
3,000
0.0045%
$10.87$32,603+22.61%
2021-08-20SaleChief Accounting Officer
1,129
0.0016%
$15.89$17,940+3.07%
2021-08-19SaleChief Accounting Officer
2,802
0.004%
$16.02$44,888+2.50%
2021-05-24Purchasedirector
10,000
0.0112%
$13.46$134,619+21.34%
2021-05-21Purchasedirector
10,000
0.0111%
$12.97$129,670+24.75%
2021-05-20Sale10 percent owner
32.01M
33.288%
$12.25$392.06M+23.35%
2020-02-24SaleChief Accounting Officer
2,954
0.003%
$14.78$43,660-14.60%
2019-02-27Purchasedirector
15,000
0.0148%
$15.90$238,500-13.22%
2019-02-26SaleChief Accounting Officer
5,617
0.0055%
$16.00$89,872-13.92%

Insider Historical Profitability

8.69%
DENNER ALEXANDER J10 percent owner
7277000
11.6244%
$19.04100+6.89%
Winningham Rick EChief Executive Officer
690106
1.1024%
$19.04110+19.65%
Shafer Bradford JSr VP, Gen. Counsel, Secretary
446274
0.7129%
$19.0419<0.0001%
GLICK MARTYExecutive VP, Finance and CFO
267805
0.4278%
$19.0410<0.0001%
BLUM LEONARD MSr VP, Chief Comm. Officer
158618
0.2534%
$19.0430+41.56%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$154.57M16.2410.14M-2.03%-$3.2M<0.01
Sarissa Capital Management LP$110.9M11.657.28M0%+$019.4
The Vanguard Group$95.8M10.076.29M-6.35%-$6.5M<0.01
Franklin Templeton Investments$95.58M10.046.27M+13,628.29%+$94.88M0.03
Dimensional Fund Advisors$70.31M7.394.61M+2.13%+$1.47M0.02
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.